Related Experiment Video
Updated: Oct 26, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population
Ariel Israel1, Alejandro A Schäffer2, Assi Cicurel1,3
1Division of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel.
Insights
Certain cholesterol pathway medications like ubiquinone, ezetimibe, and rosuvastatin show promise in reducing COVID-19 hospitalization risk. Further research is needed to confirm these protective effects against severe coronavirus disease 2019.
Area of Science:
- Epidemiology
- Pharmacology
- Public Health
Background:
- Investigating existing medications for protective effects against severe coronavirus disease 2019 (COVID-19) is crucial due to limited accessibility of specific COVID-19 treatments.
- A large population study was conducted within Clalit Health Services (CHS), Israel's largest healthcare provider, covering over 4.7 million members.
Purpose of the Study:
- To identify medications acquired within the last month that decrease the risk of COVID-19 hospitalization.
- To assess the association between medication use and reduced severity of COVID-19 outcomes.
Main Methods:
- Two matched case-control cohorts were assembled, including adults aged 18-95 hospitalized for COVID-19 (cases).
- Cohort 1: Five controls from the general population per case (n=6202). Cohort 2: Two non-hospitalized SARS-CoV-2 positive controls per case (n=6919).
- Odds ratios (OR), 95% confidence intervals (CI), and p-values were calculated using Fisher's exact test, with false discovery rate adjustment for multiple testing.
Main Results:
- Significantly reduced odds for COVID-19 hospitalization were associated with ubiquinone (OR=0.185), ezetimibe (OR=0.488), rosuvastatin (OR=0.673), flecainide (OR=0.301), and vitamin D (OR=0.869).
- Notably, artificial tears, eye care products, and ophthalmologicals also showed a decreased risk of hospitalization.
- Medications linked to the cholesterol synthesis pathway (ubiquinone, ezetimibe, rosuvastatin) demonstrated a protective effect.
Conclusions:
- Ubiquinone, ezetimibe, and rosuvastatin, involved in cholesterol synthesis, were associated with lower COVID-19 hospitalization rates.
- These findings suggest a potential protective role for these medications against severe COVID-19.
- Further investigation in controlled, prospective studies is warranted to confirm these promising results.
Background:
Until coronavirus disease 2019 (COVID-19) drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether existing medications have a protective effect against severe disease. Toward this objective, we conducted a large population study in Clalit Health Services (CHS), the largest healthcare provider in Israel, insuring over 4.7 million members.
Methods:
Two case-control matched cohorts were assembled to assess which medications, acquired in the last month, decreased the risk of COVID-19 hospitalization. Case patients were adults aged 18 to 95 hospitalized for COVID-19. In the first cohort, five control patients, from the general population, were matched to each case (n=6202); in the second cohort, two non-hospitalized SARS-CoV-2 positive control patients were matched to each case (n=6919). The outcome measures for a medication were: odds ratio (OR) for hospitalization, 95% confidence interval (CI), and the p-value, using Fisher's exact test. False discovery rate was used to adjust for multiple testing.
Results:
Medications associated with most significantly reduced odds for COVID-19 hospitalization include: ubiquinone (OR=0.185, 95% CI [0.058 to 0.458], p<0.001), ezetimibe (OR=0.488, 95% CI [0.377 to 0.622], p<0.001), rosuvastatin (OR=0.673, 95% CI [0.596 to 0.758], p<0.001), flecainide (OR=0.301, 95% CI [0.118 to 0.641], p<0.001), and vitamin D (OR=0.869, 95% CI [0.792 to 0.954], p<0.003). Remarkably, acquisition of artificial tears, eye care wipes, and several ophthalmological products were also associated with decreased risk for hospitalization.
Conclusions:
Ubiquinone, ezetimibe, and rosuvastatin, all related to the cholesterol synthesis pathway were associated with reduced hospitalization risk. These findings point to a promising protective effect which should be further investigated in controlled, prospective studies.
Funding:
This research was supported in part by the Intramural Research Program of the National Institutes of Health, NCI.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Controls in Experiments
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Single Nucleotide Polymorphisms-SNPs
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Classes and Categories

